2. Immunology/Inflammation
  3. PD-1/PD-L1
  4. Latikafusp

Latikafusp  (Synonyms: AMG 256)

Cat. No.: HY-P99687 Purity: 99.00%
COA

Molarity Calculator

Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research.Latikafusp may lead to the development of immunogenicity-mediated responses.

For research use only. We do not sell to patients.

CAS No. : 2552814-07-8

Size Price Stock Quantity
500 μg USD 405 In-stock
1 mg USD 650 In-stock
5 mg USD 1690 In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Latikafusp Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research[1][2].Latikafusp may lead to the development of immunogenicity-mediated responses[3].

Isotype

Human IgG1 lambda1
Recommend Isotype Controls
Species

Human
In Vivo

Latikafusp (5 mg/kg; administered on days 1 and 15; i.v.) induces significant immunogenicity and hypersensitivity in cynomolgus monkeys[3].
Latikafusp (10, 30 mg/kg; Weekly doses over three weeks; i.v.) activates both classical and alternative complement pathways[3].
Latikafusp (10, 30 mg/kg; Weekly doses over three weeks; i.v.) causes cynomolgus monkeys in all dose groups to show strong antibody responses, suggesting that the drug has high immunogenicity[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Cynomolgus monkeys [3]
Dosage: 5 mg/kg; administered on days 1 and 15
Administration: i.v.
Result: Elicited a strong immunogenic response in all animals, as evidenced by the presence of anti-Latikafusp IgG antibodies on days 15 and 25 following the initial dose administration.
Compared to the 22D4 group alone, the antibody response was significantly higher.
Animal Model: Cynomolgus monkeys [3]
Dosage: 10, 30 mg/kg; Weekly doses over three weeks
Administration: i.v.
Result: Induced the development of anti-Latikafusp IgG antibodies in all animals by day 19, demonstrating a strong immune response to the therapeutic protein.
Administration in high doses led to severe adverse reactions and immunogenic complications, underscoring critical safety concerns associated with its use.
Animal Model: Cynomolgus monkeys [3]
Dosage: 0, 6, 30, or 150 mg/kg; Weekly doses over four weeks
Administration: i.v.
Result: At the highest dose of 150 mg/kg, caused severe clinical signs in animals, including weakness, petechiae, hypothermia, and dehydration, which led to the unscheduled euthanasia of several animals.
Additionally, at high doses was linked to immunogenicity-related complications, such as thrombocytopenia and consumptive coagulopathy.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Latikafusp]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 lambda
Biological Activity
  • Loaded Latikafusp on HIS1K biosensor, can bind PD-1 Protein, Human (HEK293, His-Fc, HY-P73345) with an affinity constant of 9.162E-11 M as determined in BLI assay.
Purity & Documentation

Purity: 99.00%

COA (232 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Latikafusp Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Latikafusp2552814-07-8AMG 256AMG256AMG-256PD-1/PD-L1PD-1/Programmed death-ligand 1BifunctionalPD-1antibodyIL-21 muteincytotoxicmemory T cellsolid tumorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Latikafusp
Cat. No.:
HY-P99687
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.